Argos, the inhibitor of the Drosophila epidermal growth factor (EGF) receptor, remains the only known extracellular inhibitor of this family of receptors in any organism. The functional domain of Argos includes an atypical EGF domain and it is not clear whether it binds to the EGF receptor or if it acts via a distinct receptor to reduce Egfr activity indirectly. Here we present two lines of evidence that strongly suggest that Argos directly interacts with the EGF receptor. First, Argos is unable to inhibit a chimeric receptor that contains an extracellular domain from an unrelated RTK, indicating the need for the EGF receptor extracellular domain. Second, Argos can inhibit the Drosophila EGF receptor even when expressed in human cells, implying that no other Drosophila protein is necessary for inhibition. We also report that Argos and the Drosophila activating ligand, Spitz, can in¯uence mammalian RTK activation, albeit in a cell-type speci®c manner. This includes the ®rst evidence that Argos can inhibit signalling in mammalian cells, raising the possibility of engineering an eective human EGF receptor/ErbB antagonist. Oncogene (2000) 19, 3560 ± 3562.
The epidermal growth factor receptor (Egfr) is a receptor tyrosine kinase whose activity controls many aspects of cell proliferation and dierentiation. Signalling through the Egfr results in dierent cell responses depending on the strength of the signal, the cell type and its developmental stage; these functions include promoting cell survival, triggering cell dierentiation or inducing cell proliferation. Furthermore, it is also well established that overactivation of the receptor in mammals is implicated in many forms of cancer (for review see Casci and Freeman, 1999) . For these reasons, precise regulation of Egfr signalling is essential. Several classes of activating ligands have already been described, including EGF, transforming growth factor a, neuregulins and others, but there is only one candidate for an inhibitory ligand, the product of the Drosophila gene argos. Argos is a secreted protein that contains an EGF domain, and both in vivo and in vitro it has been shown to inhibit signalling through the Egfr (Freeman et al., 1992; Schweitzer et al., 1995) . Genetic experiments have shown that Argos inhibition has a crucial role in the precise regulation of the Egfr at many stages of Drosophila development (for example see Freeman, 1996; Golembo et al., 1996; Stemerdink and Jacobs, 1997) . Argos is structurally distinct from all other EGF-like factors; the B-loop of the EGF domain is signi®cantly longer (20 residues versus approximately 10) and it also requires speci®c regions outside the EGF domain for its inhibitory action (Howes et al., 1998) . These dierences, the diculties of demonstrating direct binding of Argos to the Drosophila Egfr, and the reported lack of success in constructing human Egfr antagonists by making chimeras between human EGF and Argos (Lohmeyer et al., 1997; van de Poll et al., 1997) , have led to uncertainty over whether Argos is an antagonistic ligand of Drosophila Egfr or if it acts indirectly through a yet uncharacterized receptor. Importantly, Argos can inhibit ligand-independent receptor activity, implying that it does not act by binding to the activating ligands or by preventing their binding to the receptor. Here we present results that support the hypothesis that Argos acts directly upon the Egfr, implying that it is a unique antagonistic ligand.
To investigate which parts of the EGF receptor are necessary for Argos inhibition, we used a chimeric receptor (Tor D Egfr) in which the whole extracellular and transmembrane part of the receptor is replaced with the corresponding regions from a constitutively dimerizing version of the Torso receptor tyrosine kinase. This receptor has been shown in vivo to be constitutively active and ligand independent and, like the wild-type EGF receptor, signals through the Ras/ MAP kinase pathway (Reichman-Fried et al., 1994) . We made a stable cell line in which Drosophila S2 cells, which do not express detectable levels of the Egfr, were transformed with Tor (Figure 1 ). In contrast, when the wildtype receptor is expressed in these cells, it has only low constitutive activity; this is stimulated by the addition of the activating ligand Spitz, and inhibited by Argos. Chimeric receptor phosphorylation was solely dependent on receptor levels and, in agreement with in vivo data (Reichman-Fried et al., 1994) , was independent of the presence of Spitz. Importantly, this ligand independent phosphorylation is also insensitive to Argos. This demonstrates that Argos inhibition of receptor phosphorylation requires the extracellular domain of the Egfr, and further supports the hypothesis that Argos binds to the Egfr and not to some other receptor whose activity aects the tyrosine phosphorylation/dephosphorylation rates of the Egfr.
In a second experiment, we assayed the ability of Argos to inhibit the Drosophila Egfr expressed in human cells. In this way we tested whether any other Drosophila proteins are necessary for inhibition. Using standard experimental conditions, we could not detect any eect of Spitz and Argos on endogenous RTK activation in HEK-293 cells (but see below). Upon transient transfection of these cells with Drosophila Egfr under control of the CMV promoter we were able to detect high levels of Drosophila Egfr in the cell membrane of transfected cells (Figure 2a,b) . These transfected 293 cells adopted a rounder more compact morphology instead of their usual spread, ®broblast like appearance (Figure 2a ), although it is not clear what the cause of this change is. We ®nd that the Drosophila Egfr is capable of activating the human MAP kinase signalling pathway (Figure 2b) , demonstrating a high degree of structural conservation in the intracellular part of Egfr signalling over 600 million years of evolution. In these Drosophila Egfr-expressing 293 cells, Spitz activates Drosophila Egfr strongly, as detected by MAPK phosphorylation (Figure 2b , 1994) , was placed under control of the metallothionein promoter in the vector pRmHa3. A stable line of S2 cells that express this chimeric receptor was generated and the sensitivity of the receptor to Spitz and Argos was tested. Secreted Spitz-conditioned medium (sSpitz) and Argos-conditioned medium (Aos) were added; neither aected the phosphorylation levels of the chimeric receptor. (b) Control S2 cells expressing wild-type Egfr show an increase in receptor phosphorylation in the absence of Spitz medium. This activation is eectively inhibited by Argos medium. Secreted Spitz-conditioned medium is serum-free Schneider's from S2-sspi cultures induced to produce a secreted form of Spitz. Argosconditioned medium is serum-free CCM3 (Hyclone) from Sf9 cultures infected with a baculovirus expressing Argos (see Schweitzer et al. (1995) ). Tor D Egfr expression in S2-Tor D Egfr cells was induced with CuSO4 for 2 h at the indicated concentrations and washed in medium without serum; Argos and/or Spitz media were added at dilution factors of 0.2 and 0.5, respectively. After 10 min incubation at room temperature, the cells were resuspended in RIPA buer on ice and incubated at 48C overnight in the presence of 1/500 guinea-pig anti-Egfr, followed by 1 h incubation with protein-A sepharose beads. After immunoprecipitation, samples were resuspended in SDS sample buer and incubated at 908C for 3 min. Samples were electrophoresed, blotted, and incubated with the anti-phosphotyrosine antibody (PY20, Transduction Laboratories) at 1:1000 dilution, followed by a secondary HRP conjugated anti-mouse, and developed using ECL Plus (Amersham) Figure 2 The Drosophila Egfr can be inhibited by Argos in human cells. (a) Human embryonic kidney 293 (HEK-293) cells transfected with a construct that constitutively expresses Drosophila Egfr (CMV-DER), were stained with a rabbit polyclonal anti-Egfr antibody against the extracellular domain of the receptor in the absence of detergent. Note the peripheral staining and the dierent, rounder appearance of transfected cells (a transfected cell is indicated with a black arrow; an untransfected cell with a white arrow). (b) 293 cells and CMV-DER transfected 293 cells were incubated in the presence of Argos, and/or Spitz-conditioned medium or control medium. The top panel shows expression of Drosophila Egfr in the transfected cells; it is not known why the receptor appears as a doublet in these cells. The lower panel shows human MAPK activation in response to control medium, or Spitz and/or Argos-conditioned medium in the same cells. In human cells, Drosophila Egfr retains the ability of being activated by Spitz, and that activation can be blocked by Argos. HEK-293 cells grown on alpha-MEM with 10% FCS, were transiently transfected with the Drosophila Egfr under control of the human cytomegalovirus early promoter (CMV) by calcium phosphate-DNA coprecipitation. After 12 h recovery, cells were washed with serum-free medium and treated in the same way as in Figure 1 . After electrophoresis and Western blotting of samples, activation of the Drosophila Egfr was followed using a monoclonal antibody speci®c for activated MAP kinase (MAPK-YT, Sigma; see also Gabay et al. (1997) ). Drosophila Egfr expression was detected by incubation of the top part of the blot with rabbit polyclonal anti-Egfr. Secreted Spitzconditioned medium (sSpitz) and Argos-conditioned medium (Aos) were added at same dilutions as in Figure 1 via an intermediate. It has been previously shown that Argos does not act by binding to and inactivating Spitz (Schweitzer et al., 1995) .
In summary, these results strongly support the hypothesis that Argos is a direct antagonist of the Drosophila Egfr. They are inconsistent with the existence of a distinct receptor that mediates the inhibitory function of Argos.
Given the clinical signi®cance of hyperactivity of the ErbB receptors, attempts have been made to exploit the clear structural dierences between the EGF domains of Argos and activating ligands to try to produce human Egfr antagonists (Lohmeyer et al., 1997; van de Poll et al., 1997) . These attempts have been largely unsuccessful. One possible reason for this is that we have subsequently shown that Argos biological activity requires not only its unusual EGF domain, but also sequences outside it (Howes et al., 1998) . These chimeras were synthesized because there was no evidence that Argos itself can act on human ErbB receptors. We report here that there is, in fact, a weak response to both Spitz and Argos in mammalian cells. Interestingly, this regulation of endogenous RTK signalling in response to Spitz and Argos is cell linespeci®c. As reported above, we did not detect a response of 293 cells to Spitz and Argos under normal conditions. However, with much longer exposure of the gel, we see clear activation of MAPK induced by Spitz and this is inhibited by the addition of Argos ( Figure  3a ). We do not know which endogenous receptor stimulates this MAP kinase activation, but as the Drosophila Egfr is similar to all four of the ErbB receptors, we speculate that one of these is the likely candidate. HeLa and COS cells show a much higher basal level of MAPK phosphorylation and this was not aected by Spitz or Argos (not shown).
Two other human cell lines, A431 and KB, responded dierently to Argos. Although neither line responded to the addition of Spitz (activation of A431 cells by secreted Spitz medium, Figure 3c , lane 2, could be attributed to control medium in the absence of Spitz, Figure 3c , lane 5), both cell types responded to Argos with a strong increase in MAPK phosphorylation not seen in control medium (Figure 3b ). It is worth noting that both cell types were established from human epithelial carcinomas and express very high levels of EGF receptor. It would be interesting to establish if their response to Argos is typical of skin cells or if it is a re¯ection of their transformation process.
These results show that in some contexts Argos can activate RTK signalling, although we do not know the determinant of this response. They also indicate that in any attempt to engineer Argos-related inhibitory ligands, attention must be given to the cell line used in the assay; for example, in one case A431 cells were used to assay the activity of human EGF-Argos chimeras (Lohmeyer et al., 1997) : in the light of our data, these would seem to be a poor choice and it might be worth retesting the chimeras in other cells. Finally, our observation that, at least in some cells, Argos can inhibit mammalian RTK signalling, opens the possibility of introducing changes in its sequence that would increase its potency, with the goal of designing an anti-oncogenic agent. Untransfected HEK-293 cells display a higher level of MAPK activation in response to secreted Spitz-conditioned medium, but not to control medium (c). MAPK phosphorylation can be suppressed even below basal levels by the addition of Argosconditioned medium. (b) Untransfected human A431 and KB cells induced very high levels of MAPK phosphorylation upon addition of Argos-conditioned medium. The response of A431 cells to Spitz-conditioned medium could not be attributed to Spitz, since the cells also reacted strongly with the Spitz control medium that lacks Spitz (c). COS, KB, and A431 cells were grown in DMEM (BRL) with 10% FCS. Samples for a and b were processed in parallel, except that the image was obtained after 2 min exposure in b and overnight exposure in a. Secreted Spitz-conditioned medium (sSpitz) and Argos-conditioned medium (Aos) were added at same dilutions as in Figure 2 
